Trial Profile

A Pharmacokinetic Study in Chinese Healthy Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of Ensartinib Capsules

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ensartinib (Primary)
Indications CNS cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Betta Pharmaceuticals Co Ltd

Most Recent Events

01 Mar 2022 Results evaluating the effects of food on the pharmacokinetics of ensartinib after a single dose (225 mg) in healthy Chinese subjects, published in the Clinical and Experimental Pharmacology and Physiology
22 Jul 2019 Status changed from recruiting to completed.
17 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com